Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-refractory KRAS G12C-mutant NSCLC for Immune Checkpoint Blockade.
Wei X, Blaj C, Ali Al-Radhawi M, Lai LP, Maldonato BJ, Yang YC, Seu L, Gundlapalli H, Jiang L, Moreno Ayala MA, Spradlin JN, Garrick B, Cai S, Salmon A, Pham A, Bredeson S, Liang R, Helland C, Evans JW, Labrecque MP, Yu X, Song AHJ, Dinglasan N, Tran L, Kumamoto A, Grigoryan L, Malliri A, Brown KD, Carter M, Simpson KL, Crosbie PA, Galvin M, Chang S, Huang Y, Tovbis Shifrin N, Pechuan-Jorge X, Raghulan R, Zhuang Y, Coles DI, Dive C, Aronchik I, Holderfield M, Lindsay CR, Wang Z, Wang Z, Singh M, Smith JAM, Jiang J, Quintana E.
Wei X, et al. Among authors: jiang l.
Cancer Discov. 2026 Feb 11. doi: 10.1158/2159-8290.CD-25-1616. Online ahead of print.
Cancer Discov. 2026.
PMID: 41670434